3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Carboplatin
28
Cisplatin
25
pembrolizumab
25
Paclitaxel
22
Nivolumab
20
Gemcitabine
17
Pemetrexed
15
Rituximab
14
Ipilimumab
13
Cyclophosphamide
11
Dexamethasone
11
Fluorouracil
10
durvalumab
10
Capecitabine
9
Docetaxel
9
trastuzumab deruxtecan
9
Lenalidomide
8
Oxaliplatin
8
atezolizumab
8
Doxorubicin
7
daratumumab
7
osimertinib
7
Bortezomib
6
Cytarabine
6
Leucovorin
6
Sunitinib
6
Trastuzumab
6
olaparib
6
venetoclax
6
130-nm albumin-bound paclitaxel
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
polatuzumab vedotin
×
1 year
×
Clear all
NCT03274492
2026-05-08
POLARIX
Hoffmann-La Roche
Phase 3
Completed
1,000 enrolled
1 FDA